...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian and New Zealand journal of psychiatry >Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder
【24h】

Effectiveness study of venlafaxine-XR combined with aripiprazole for chronic or recurrent major depressive disorder

机译：文拉法辛-XR联合阿立哌唑治疗慢性或复发性重度抑郁症的有效性研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective: Although the second-generation antipsychotic, aripiprazole (ARI), has been approved as an adjunct for treatment-resistant major depressive disorder (MDD), neither ARI nor any second-generation antipsychotic has been assessed in combination with an antidepressant at the initiation of a treatment trial for non-treatment-resistant MDD. The aim of the present study was therefore to assess the safety, tolerability, and remission rate in the treatment of MDD using the specific combination of venlafaxine-XR (VEN-XR) and ARI in a generalizable, difficult-to-treat group with chronic or recurrent MDD. Methods: Self-declared participants in primary care or psychiatric settings who had chronic or recurrent MDD and a minimum score of 14 on the 17-item Hamilton Rating Scale for Depression were included. Up to 12 weeks of open treatment with the combination of VEN-XR and ARI was provided. Participants began with VEN-XR, and ARI was added at week 2. Maximum allowable doses were 300 mg day for venlafaxine-XR and 30 mg day"1 for ARI. Remission was defined as <5 on the 16-item Quick Inventory of Depressive Symptomatology-Self-report (QIDS-SR_(16)).Results: Fifty outpatients with non-psychotic MDD were enrolled (mean age =43 + 11 years; 38% male; QIDS-SR_(16) = 15+-3). Mean exit dose of VEN-XR was 227 + 97 mg day"1, and the mean exit dose of ARI was 11 +7 mg day"1. The combination was well tolerated; 16% of participants discontinued due to side-effects. Approximately 70% achieved remission at some point during the trial, and 66% achieved remission at study exit.Conclusions: To the best of the authors' knowledge this is the first study to combine an antidepressant and second-generation antipsychotic at the beginning of a treatment trial for chronic or recurrent non-treatment resistant MDD. VEN-XR and ARI combination appears to warrant further study in controlled trials.
机译：目的：尽管第二代抗精神病药物阿立哌唑（ARI）已被批准为治疗难治性重性抑郁症（MDD）的辅助药物，但开始时尚未评估ARI和任何第二代抗精神病药物与抗抑郁药的联合使用非抗药性MDD的治疗试验。因此，本研究的目的是评估在泛化，难治性慢性病组中使用文拉法辛-XR（VEN-XR）和ARI的特定组合来评估MDD治疗MDD的安全性，耐受性和缓解率或复发性MDD。方法：纳入自我宣布的患有慢性或复发性MDD且在17个项目的汉密尔顿抑郁量表中至少得分为14的基层医疗或精神病学参与者。提供VEN-XR和ARI组合长达12周的开放治疗。参加者从VEN-XR开始，并在第2周加入ARI。文拉法辛-XR的最大允许剂量为300毫克/天，ARI的最大允许剂量为30毫克/天“ 1”。在16项抑郁症快速调查中，缓解率定义为<5症状自我报告（QIDS-SR_（16））。结果：招募了50名非精神病性MDD门诊患者（平均年龄= 43 + 11岁;男性38％; QIDS-SR_（16）= 15 + -3）。 VEN-XR的平均退出剂量为227 + 97 mg第一天“ 1，而ARI的平均退出剂量为11 +7 mg第一天”1。该组合耐受性良好; 16％的参与者因副作用而中止。在试验过程中的某个时候，大约有70％的患者达到了缓解，而在研究退出时，有66％的患者达到了缓解。结论：据作者所知，这是在抗抑郁药开始时将抗抑郁药和第二代抗精神病药联合使用的第一项研究。慢性或复发性非耐药性MDD的治疗试验VEN-XR和ARI的结合似乎值得在对照试验中进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号